Sclerostin
- PMID: 20981340
- PMCID: PMC2957275
- DOI: 10.4061/2010/941419
Sclerostin
Abstract
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
References
-
- van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development. 2009;136(19):3205–3214. - PubMed
-
- Kneissel M. The promise of sclerostin inhibition for the treatment of osteoporosis. IBMS BoneKEy. 2009;6:259–264.
-
- Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Human Molecular Genetics. 2001;10(5):537–543. - PubMed
-
- Wengenroth M, Vasvari G, Federspil PA, Mair J, Schneider P, Stippich C. Case 150: Van Buchem disease (hyperostosis corticalis generalisata) Radiology. 2009;253(1):272–276. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources